FDA expands use of Allergan's Botox to include overactive bladder

01/20/2013 | Reuters · MedPage Today (free registration)

Allergan's Botox, or onabotulinumtoxin A, has been approved by the FDA for use in patients with overactive bladder who can't take or don't improve with anticholinergics. The approval was based on results of two clinical studies showing that Botox reduced the frequency of incontinence and urination compared with placebo.

View Full Article in:

Reuters · MedPage Today (free registration)

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Counsel, Regulatory (FDA)
San Diego , CA
Health Care Exchange Account Manager
Kaiser Permanente
San Diego, CA
Director, Health Plan Claims Operations
Group Health Cooperative
Seattle, WA
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Field Representative-Oklahoma and Kansas
National Rural Electric Cooperative Association (NRECA)
Multiple Locations, SL_Multiple Locations